Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.
- Resource Type
- letter
- Authors
- Bradley, Todd; Grundberg, Elin; Selvarangan, Rangaraj; LeMaster, Cas; Fraley, Elizabeth; Banerjee, Dithi; Belden, Bradley; Louiselle, Daniel; Nolte, Nick; Biswell, Rebecca; Pastinen, Tomi; Myers, Angela; Schuster, Jennifer
- Source
- New England Journal of Medicine. 5/20/2021, Vol. 384 Issue 20, p1959-1961. 3p.
- Subject
- *SARS-CoV-2
*ANTIBODY formation
*MEDICAL personnel
- Language
- ISSN
- 0028-4793
The article informs antibody responses after a single dose of SARS-CoV-2 mRNA vaccine that involve messenger RNA platform technology have been approved for emergency use by the Food and Drug Administration. Topics include Phase 3 trials of vaccines showed greater efficacy at preventing symptomatic infection after two doses with trials primarily involved participants without previous SARS-CoV-2 infection; and biospecimens from vaccine recipients were obtained in the context of a clinical study.